Psychosocial and economic issues related to physical health in psychiatric illness

European Neuropsychopharmacology

Volumn 18, Issue SUPPL. 2, 2008, Pages S115-S120

  Thomas, Pierre ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Antipsychotics; Extrapyramidal symptoms; Quality of life; Schizophrenia; Sexual dysfunction; Weight gain

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; AUTONOMIC DYSFUNCTION; DIET THERAPY; DISEASE EXACERBATION; ECONOMIC ASPECT; EXERCISE; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HEALTH STATUS; HUMAN; MENTAL PATIENT; MUSCLE SPASM; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL ASPECT; STIGMA; WEIGHT GAIN; ECONOMICS; MENTAL DISEASE; MENTAL HEALTH; REVIEW; SOCIAL BEHAVIOR;

HEALTH STATUS; HUMANS; MENTAL DISORDERS; MENTAL HEALTH; SOCIAL BEHAVIOR; WEIGHT GAIN;

EID: 40749136279     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.02.005     Document Type: Article

References (40)

1. ADA. Economic costs of diabetes in the US in 2002. Diabetes Care 26 (2003) 917-932
2. ADA. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
3. Allison D.B., and Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 62 (2001) 22-31
4. Allison D.B., Fontaine K.R., Heo M., Mentore J.L., Cappelleri J.C., Chandler L.P., Weiden P.J., and Cheskin L.J. The distribution of body mass index among individuals with and without schizophrenia. J. Clin. Psychiatry 60 (1999) 215-220
5. Allison D.B., Mackell J.A., and McDonnell D.D. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr. Serv. 54 (2003) 565-567
6. Andrews G., Sanderson K., Corry J., Issakidis C., and Lapsley H. Cost-effectiveness of current and optimal treatment for schizophrenia. Br. J. Psychiatry 183 (2003) 427-435 discussion 436
7. Aronne L.J. Epidemiology, morbidity, and treatment of overweight and obesity. J. Clin. Psychiatry 62 (2001) 13-22
8. Awad A.G., and Voruganti L.N. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18 (2004) 877-893
9. Bobes J., Canas F., Rejas J., and Mackell J. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 1287-1297
10. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br. J. Psychiatry 171 (1997) 502-508
11. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol. Med. 22 (1992) 787-797
12. Connolly M., and Kelly C. Lifestyle and physical health in schizophrenia. Adv. Psychiatr. Treat 11 (2005) 125-132
13. De Hert M., Peuskens B., van Winkel R., Kalnicka D., Hanssens L., Van Eyck D., Wyckaert S., and Peuskens J. Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. Schizophr. Res. 88 (2006) 222-226
14. Dubisar B.M., Stoner S.C., Reynolds J., Khan R., and Ramlatchman L. Adverse effects of atypical antipsychotic agents and their effects on quality of life. Pharmacotherapy 24 (2004) 843-847
15. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann. Clin. Psychiatry 14 (2002) 47-57
16. Goff, D.C., Cather, C., Evins, A.E., Henderson, D.C., Freudenreich, O., Copeland, P.M., Bierer, M., Duckworth, K., Sacks, F.M. 2005. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 66, 183--194; quiz 147, 273--284.
17. Hamilton S.H., Edgell E.T., Revicki D.A., and Breier A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int. Clin. Psychopharmacol. 15 (2000) 245-255
18. Hofer A., Kemmler G., Eder U., Edlinger M., Hummer M., and Fleischhacker W.W. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry 65 (2004) 932-939
19. Joukamaa M., Heliovaara M., Knekt P., Aromaa A., Raitasalo R., and Lehtinen V. Mental disorders and cause-specific mortality. Br. J. Psychiatry 179 (2001) 498-502
20. Joyce A.T., Harrison D.J., Loebel A.D., and Ollendorf D.A. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am. J. Manag. Care 11 (2005) S254-S261
21. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., Schimmelmann B.G., and Naber D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J. Clin. Psychiatry 68 (2007) 75-80
22. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., and Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64 (2007) 633-647
23. Kerwin R., Millet B., Herman E., Banki C.M., Lublin H., Pans M., Hanssens L., L'Italien G., McQuade R.D., and Beuzen J.-N. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) study. Eur. Psychiatr. 22 (2007) 433-443
24. Knapp M., King D., Pugner K., and Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br. J. Psychiatry 184 (2004) 509-516
25. Kolotkin R.L., Crosby R.D., Kosloski K.D., and Williams G.R. Development of a brief measure to assess quality of life in obesity. Obes. Res. 9 (2001) 102-111
26. Kolotkin R.L., Crosby R.D., Corey-Lisle P.K., Li H., and Swanson J.M. Performance of a weight-related measure of quality of life in a psychiatric sample. Qual. Life Res. 15 (2006) 587-596
27. Kurzthaler I., and Fleischhacker W.W. The clinical implications of weight gain in schizophrenia. J. Clin. Psychiatry 62 (2001) 32-37
28. Lambert M., Conus P., Eide P., Mass R., Karow A., Moritz S., Golks D., and Naber D. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur. Psychiatr. 19 (2004) 415-422
29. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
30. McDonald M., Hertz R.P., Lustik M.B., and Unger A.N. Healthcare spending among community-dwelling adults with schizophrenia. Am. J. Manag. Care 11 (2005) S242-S247
31. Mubarak A.R. Social functioning and quality of life of people with schizophrenia in the northern region of Malaysia. AeJAMH 4 1 (2005)
32. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (2005) 1-93
33. Olfson M., Uttaro T., Carson W.H., and Tafesse E. Male sexual dysfunction and quality of life in schizophrenia. J. Clin. Psychiatry 66 (2005) 331-338
34. Ritsner M., Gibel A., Perelroyzen G., Kurs R., Jabarin M., and Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J. Clin. Psychopharmacol. 24 (2004) 582-591
35. Roick C., Fritz-Wieacker A., Matschinger H., Heider D., Schindler J., Riedel-Heller S., and Angermeyer M.C. Health habits of patients with schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. 42 (2007) 268-276
36. Rosenberg K.P., Bleiberg K.L., Koscis J., and Gross C. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J. Sex Marital Ther. 29 (2003) 289-296
37. Salokangas R.K., Honkonen T., Stengard E., and Koivisto A.M. Subjective life satisfaction and living situations of persons in Finland with long-term schizophrenia. Psychiatr. Serv. 57 (2006) 373-381
38. Schimmelmann B.G., Paulus S., Schacht M., Tilgner C., Schulte-Markwort M., and Lambert M. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J. Child Adolesc. Psychopharmacol. 15 (2005) 249-258
39. Stallard J., and Joyce E. The impact of olanzapine on attitude to medication and quality of life in schizophrenia. Psychiatr. Bull. 25 (2001) 378-381
40. Weiden P.J., and Olfson M. Cost of relapse in schizophrenia. Schizophr. Bull. 21 (1995) 419-429